Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease

Maria Vittoria Arcidiacono, Erika Rimondi, Elisa Maietti, Elisabetta Melloni, Veronica Tisato, Stefania Gallo, Jose Manuel Valdivielso, Elvira Fernández, Àngels Betriu, Rebecca Voltan, Giorgio Zauli, Stefano Volpato, Paola Secchiero

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Chronic kidney disease (CKD) patients experience a high risk of cardiovascular disease (CV); however, the factors involved in CV-related morbidity and mortality in these patients have not been fully defined. Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) is a cytokine, which exhibits pleiotropic activities on endothelial, vascular smooth muscle and inflammatory cells, with relevant effects on atheromatous plaque formation. On this basis, the present study aims to investigate the role of TRAIL in atheromatosis progression in CKD patients. Methods Circulating TRAIL levels were measured in 378 CKD patients belonging to the Spanish National Observatory of Atherosclerosis in Nephrology (NEFRONA) study. All patients were free of previous CV events. Carotid and femoral B-mode ultrasound was performed to detect the presence of plaque at baseline and after 24 months of follow-up. Results The lowest levels of TRAIL at baseline were significantly (p<0.05) associated with the appearance, after 24 months of follow-up, of at least two new atheromatous plaques in all territories and of one new plaque in the carotid artery, even after adjusting for CV risk factors. In addition, the patients with low levels of TRAIL at baseline were characterized by the presence of at least one hypoechoic plaque in the carotid artery. This association was significant (p<0.05) even after adjusting for CKD stage. Conclusions Overall, the results of our study suggest TRAIL as an assertable independent prognostic biomarker for atheromatosis plaque formation in CKD patients. This observation further supports the potential role of TRAIL for the prevention/treatment of CV disease.

Original languageEnglish
Article numbere0203716
JournalPLoS One
Volume13
Issue number9
DOIs
Publication statusPublished - Sep 1 2018

Fingerprint

tumor necrosis factors
kidney diseases
Chronic Renal Insufficiency
apoptosis
Tumor Necrosis Factor-alpha
Apoptosis
Ligands
cardiovascular diseases
Cardiovascular Diseases
carotid arteries
Carotid Stenosis
Atherosclerotic Plaques
Nephrology
Hong Kong
thighs
Thigh
ligands
atherosclerosis
Vascular Smooth Muscle
blood vessels

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Arcidiacono, M. V., Rimondi, E., Maietti, E., Melloni, E., Tisato, V., Gallo, S., ... Secchiero, P. (2018). Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease. PLoS One, 13(9), [e0203716]. https://doi.org/10.1371/journal.pone.0203716

Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease. / Arcidiacono, Maria Vittoria; Rimondi, Erika; Maietti, Elisa; Melloni, Elisabetta; Tisato, Veronica; Gallo, Stefania; Valdivielso, Jose Manuel; Fernández, Elvira; Betriu, Àngels; Voltan, Rebecca; Zauli, Giorgio; Volpato, Stefano; Secchiero, Paola.

In: PLoS One, Vol. 13, No. 9, e0203716, 01.09.2018.

Research output: Contribution to journalArticle

Arcidiacono, MV, Rimondi, E, Maietti, E, Melloni, E, Tisato, V, Gallo, S, Valdivielso, JM, Fernández, E, Betriu, À, Voltan, R, Zauli, G, Volpato, S & Secchiero, P 2018, 'Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease', PLoS One, vol. 13, no. 9, e0203716. https://doi.org/10.1371/journal.pone.0203716
Arcidiacono, Maria Vittoria ; Rimondi, Erika ; Maietti, Elisa ; Melloni, Elisabetta ; Tisato, Veronica ; Gallo, Stefania ; Valdivielso, Jose Manuel ; Fernández, Elvira ; Betriu, Àngels ; Voltan, Rebecca ; Zauli, Giorgio ; Volpato, Stefano ; Secchiero, Paola. / Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease. In: PLoS One. 2018 ; Vol. 13, No. 9.
@article{e54f853b70074a9fa72c0ed64212a646,
title = "Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease",
abstract = "Background Chronic kidney disease (CKD) patients experience a high risk of cardiovascular disease (CV); however, the factors involved in CV-related morbidity and mortality in these patients have not been fully defined. Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) is a cytokine, which exhibits pleiotropic activities on endothelial, vascular smooth muscle and inflammatory cells, with relevant effects on atheromatous plaque formation. On this basis, the present study aims to investigate the role of TRAIL in atheromatosis progression in CKD patients. Methods Circulating TRAIL levels were measured in 378 CKD patients belonging to the Spanish National Observatory of Atherosclerosis in Nephrology (NEFRONA) study. All patients were free of previous CV events. Carotid and femoral B-mode ultrasound was performed to detect the presence of plaque at baseline and after 24 months of follow-up. Results The lowest levels of TRAIL at baseline were significantly (p<0.05) associated with the appearance, after 24 months of follow-up, of at least two new atheromatous plaques in all territories and of one new plaque in the carotid artery, even after adjusting for CV risk factors. In addition, the patients with low levels of TRAIL at baseline were characterized by the presence of at least one hypoechoic plaque in the carotid artery. This association was significant (p<0.05) even after adjusting for CKD stage. Conclusions Overall, the results of our study suggest TRAIL as an assertable independent prognostic biomarker for atheromatosis plaque formation in CKD patients. This observation further supports the potential role of TRAIL for the prevention/treatment of CV disease.",
author = "Arcidiacono, {Maria Vittoria} and Erika Rimondi and Elisa Maietti and Elisabetta Melloni and Veronica Tisato and Stefania Gallo and Valdivielso, {Jose Manuel} and Elvira Fern{\'a}ndez and {\`A}ngels Betriu and Rebecca Voltan and Giorgio Zauli and Stefano Volpato and Paola Secchiero",
year = "2018",
month = "9",
day = "1",
doi = "10.1371/journal.pone.0203716",
language = "English",
volume = "13",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

TY - JOUR

T1 - Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease

AU - Arcidiacono, Maria Vittoria

AU - Rimondi, Erika

AU - Maietti, Elisa

AU - Melloni, Elisabetta

AU - Tisato, Veronica

AU - Gallo, Stefania

AU - Valdivielso, Jose Manuel

AU - Fernández, Elvira

AU - Betriu, Àngels

AU - Voltan, Rebecca

AU - Zauli, Giorgio

AU - Volpato, Stefano

AU - Secchiero, Paola

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Background Chronic kidney disease (CKD) patients experience a high risk of cardiovascular disease (CV); however, the factors involved in CV-related morbidity and mortality in these patients have not been fully defined. Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) is a cytokine, which exhibits pleiotropic activities on endothelial, vascular smooth muscle and inflammatory cells, with relevant effects on atheromatous plaque formation. On this basis, the present study aims to investigate the role of TRAIL in atheromatosis progression in CKD patients. Methods Circulating TRAIL levels were measured in 378 CKD patients belonging to the Spanish National Observatory of Atherosclerosis in Nephrology (NEFRONA) study. All patients were free of previous CV events. Carotid and femoral B-mode ultrasound was performed to detect the presence of plaque at baseline and after 24 months of follow-up. Results The lowest levels of TRAIL at baseline were significantly (p<0.05) associated with the appearance, after 24 months of follow-up, of at least two new atheromatous plaques in all territories and of one new plaque in the carotid artery, even after adjusting for CV risk factors. In addition, the patients with low levels of TRAIL at baseline were characterized by the presence of at least one hypoechoic plaque in the carotid artery. This association was significant (p<0.05) even after adjusting for CKD stage. Conclusions Overall, the results of our study suggest TRAIL as an assertable independent prognostic biomarker for atheromatosis plaque formation in CKD patients. This observation further supports the potential role of TRAIL for the prevention/treatment of CV disease.

AB - Background Chronic kidney disease (CKD) patients experience a high risk of cardiovascular disease (CV); however, the factors involved in CV-related morbidity and mortality in these patients have not been fully defined. Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) is a cytokine, which exhibits pleiotropic activities on endothelial, vascular smooth muscle and inflammatory cells, with relevant effects on atheromatous plaque formation. On this basis, the present study aims to investigate the role of TRAIL in atheromatosis progression in CKD patients. Methods Circulating TRAIL levels were measured in 378 CKD patients belonging to the Spanish National Observatory of Atherosclerosis in Nephrology (NEFRONA) study. All patients were free of previous CV events. Carotid and femoral B-mode ultrasound was performed to detect the presence of plaque at baseline and after 24 months of follow-up. Results The lowest levels of TRAIL at baseline were significantly (p<0.05) associated with the appearance, after 24 months of follow-up, of at least two new atheromatous plaques in all territories and of one new plaque in the carotid artery, even after adjusting for CV risk factors. In addition, the patients with low levels of TRAIL at baseline were characterized by the presence of at least one hypoechoic plaque in the carotid artery. This association was significant (p<0.05) even after adjusting for CKD stage. Conclusions Overall, the results of our study suggest TRAIL as an assertable independent prognostic biomarker for atheromatosis plaque formation in CKD patients. This observation further supports the potential role of TRAIL for the prevention/treatment of CV disease.

UR - http://www.scopus.com/inward/record.url?scp=85053140532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053140532&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0203716

DO - 10.1371/journal.pone.0203716

M3 - Article

AN - SCOPUS:85053140532

VL - 13

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e0203716

ER -